Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Locati, L. D.
Right arrow Articles by Licitra, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Locati, L. D.
Right arrow Articles by Licitra, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:1327-1328, 2003
© 2003 European Society for Medical Oncology

Letters to the Editor

A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland

L. D. Locati1, P. Quattrone2, P. Bossi1, A. V. Marchianò3, G Cantù4 and L. Licitra1

1 Medical Oncology Unit, Head and Neck Department; 2 Pathology Unit B; 3 Radiology Department; 4 Head and Neck Surgery Department; Istituto Nazionale Tumori, Milan, Italy

*E-mail: lisa.licitra@istitutotumori.mi.it

The first 10% of the full text of this article appears below.

Salivary gland carcinomas (SGCs) account for 1–5% of all head and neck cancers and include different histotypes. Salivary gland adenocarcinomas (SGA) represent 16% of parotid gland cancers [1].

Chemotherapy is delivered only with a palliative aim in metastatic and/or recurrent disease. The response rate ranges from 10% to 30% and complete remissions are anecdotal [2].

Immunoreactivity . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?